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Over the past decade, vascularized composite allotransplan-
tation (VCA), such as hand and face transplantation, has
become a clinical reality and a viable treatment option for
those patients suffering from complex tissue injuries or
defectsnotamenabletoconventionalreconstruction.Despite
the fact that early and intermediate functional outcomes
are highly encouraging rejection and the need for chronic
immunosuppressive treatment continue to be the bane of
VCA, preventing its broader clinical application.
Athoroughunderstandingofthemechanismsunderlying
alloimmune responses in VCA is key to establish novel
protocols for immunomodulation and tolerance induction
after this type of transplant, without the need for long-
term immunosuppression. Such advances would diminish
the risks and favor the benefits for these non-life-saving but
life-changing transplants.
This special issue is devoted to the immunology of
vascularized composite allografts. The individual authors are
leadersinthefield,withextensiveknowledgeandexpertisein
this novel and emerging field of transplantation. The goal of
this issue is to cover various specific aspects, as well as some
of the immunological challenges related to VCA. The main
f o c u si so nt o l e r a n c es t r a t e g i e sa n dh o wt h o s ea p p l yt oV C A .
Greater scrutiny is applied to immunosuppression-
induced complications in VCA recipients compared to
solid organ transplant patients since VCA is deemed life-
enhancing rather than life-saving interventions. K. V. Ravin-
dra et al. discuss the pressure to develop tolerance-inducing
strategies in VCA.
D.A.Leonardetal.provideacomprehensivereviewofthe
use of mixed chimerism approaches for tolerance induction
inthefieldofVCAwithaparticularemphasisontranslational
large animal (MGH miniature swine) protocols. The authors
also provide an interesting overview of novel cellular ther-
apies, such as regulatory T cells, regulatory dendritic cells,
or mesenchymal stem cells as potential adjuvants to mixed
hematopoietic chimerism in the development of tolerance
induction protocols for clinical VCA.
M. Siemionow and A. Klimczak discuss the Cleveland
Clinic research experience with chimerism-based experi-
mental small animal models for tolerance induction and
highlightinparticularthecomplexityofimmunomodulatory
protocols in VCA as well as their relevance and applicability
for clinical practice.
W.-C. Huang et al. review approaches to improve the
safetyoftoleranceinducingregimescurrentlyappliedtoVCA
anddiscussimmunemonitoringandtoleranceassaysthatare
critically required prior to translating such protocols in the
clinic.
Y.-R. Kuo et al. summarize the current understanding
of immunomodulation achieved by mesenchymal stem cell
(MSC) therapy and provide a possible outline for its future
clinical application in VCA.
R.Starzletal.provideahistoricallyorienteddiscussionof
cross-disciplinaryapproachestodevelopnovelpointsofview
for some of the most challenging immunological problems
in VCA, particularly the early diagnosis and assessment of
rejection. Some of these approaches and methods lie at the
intersection of medicine, immunology, mathematics, and
computerscience.Byleveragingthestrengthsandcapabilities
of each discipline to solve problems that have been resistant
to analysis in another, more rapid progress can be made in2 Clinical and Developmental Immunology
delivering novel and clinically relevant findings, diagnostics,
or therapeutic agents.
T. Hautz and colleagues review the key players and
m o l e c u l a re v e n t so fs k i ni n fl a m m a t i o na n dd i s c u s sn e w
therapies originally developed in solid organ transplantation
with particular emphasis on skin allograft rejection and how
suchtherapiescouldrelatetoVCA.Thisisofinterestsincethe
mechanismsanddynamicsofacuteandchronicskinallograft
rejectionareincompletelyunderstoodandremainthesubject
of numerous ongoing trials aimed at better understanding
o ft h eu n d e r l y i n gp a t h o p h y s i o l o g ya n da tn o v e la n dt a r g e t e d
drug development.
J. T. Schnider et al. provide an overview of graft-targeted
and delivered site-specific immunosuppression, which is
uniquely well suited for VCA due to their direct accessibility
tosuchinterventions.Theauthorshighlightthefactthatsite-
specific therapeutic effects and efficacy of systemically active
agents may enable optimal dosing, frequency, and duration
ofoverallimmunosuppressioninVCA,withminimizationor
elimination of long-term drug-related toxicity.
C. G. Wallace et al. show that intrajejunal treatment with
donor splenocytes could render recipients immunologically
hyporesponsive in a donor-specific manner in vitro.W h e n
theregimenwastestedinarodentsettingin vivo,V CAr ejec-
t i o nw a sd e l a y e db u td i dn o tr e s u l ti ni m m u n o s u p p r e s s i v e
drug-free tolerance. These encouraging data warrant further
investigation to assess the exact role and mechanisms of
intrajejunal treatment as a low-risk adjunct to prevent VCA
rejection.
Q. Liu et al. provide interesting evidence that a short-
courseofcombinedantilymphocyteserumandCyclosporine
A treatment enables indefinite VCA survival, which induces
secondary donor-specific skin and heart allograft tolerance
despitethelossofperipheralchimerism.Thesefindingsopen
upnewperspectivesfortheroleofVCAintheinductionand
maintenance of tolerance to solid organ transplants.
We hope that this series of articles will stimulate contin-
uing efforts to better understand the unique immunological
featuresof VCA comparedto solid organ transplants,andthe
development of novel strategies to induce tolerance.
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